Home
 


Pan African Clinical Trials Registry
South African Medical Research Council, South African Cochrane Centre
PO Box 19070, Tygerberg, 7505, South Africa
Telephone: +27 21 938 0506 / +27 21 938 0834     Fax: +27 21 938 0836
Email: pactradmin@mrc.ac.za     Website: www.pactr.org

Trial no.: PACTR2010030001871293 Date registered: 2010/01/26
TRIAL DESCRIPTION
Public title Pharmacokinetic study: interactions between Artemisinin-based Combination Therapies and Antiretroviral Therapies in Malawi (ARV-ACT) Phase I Step 1
Official scientific title Special populations and label expansion studies with the fixed dose combinations artemether-lumefantrine, amodiaquine-artesunate, and dihydroartemisinin-piperaquine in Zambia, Malawi and Mozambique
Brief summary describing the background
and objectives of the trial
HIV-infected people receiving antiretroviral drugs (ARVs) living in malaria-endemic areas will become infected with malaria and will need treatment with Artemisinin-based Combination Therapies (ACTs). In this first phase of our study, we will assess the pharmacokinetics and safety of ACTs when administered to malaria uninfected people receiving ARVs. Once safety has been proved, we will conduct a second phase of the study to assess efficacy of ACTs in curing malaria in people taking ARVs.
Type of trial CCT
Acronym (If the trial has an acronym then please provide) ADAPT Project
Disease(s) or condition(s) being studied HIV/AIDS , Malaria ,
Purpose of the trial Treatment
Anticipated trial start date
Actual trial start date 2010-08-03
Anticipated date of last follow up
Actual date of last follow up 2011-07-24
Anticipated target sample size (number of participants) 66   
Actual target sample size (number of participants) 74   
Recruitment status Closed to recruitment: follow up complete
Secondary Ids Issuing authority/Trial register Links to Secondary ID

STUDY DESIGN
Intervention assignment Allocation to intervention If randomised, describe how the allocation sequence was generated Describe how the allocation sequence/code was concealed from the person
allocating the participants to the intervention arms
Masking If masking / blinding was used
Parallel: different groups receive different interventions at same time during study Non-randomised Open-label (masking not used)

INTERVENTIONS
Intervention type Intervention name Dose Duration Intervention description Group size Nature of control
Control group AL (without any ARVs) 2 tablets artemether/lumefantrine (20/120mg) twice daily 3 days artemether/lumefantrine without any ARVs 6 Dose comparison
Experimental group 3TC -d4T-NVP plus AL 3TC (150mg) -d4T (30mg)-NVP (200mg) twice daily plus 2 tablets artemether/lumefantrine (20/120mg) twice daily 3 days First line ARVs plus AL 6
Experimental group 3TC -d4T-EFV plus AL 3TC (150mg) d4T (30mg) twice daily plus Efavirenz (EFV; 600mg) once daily plus 2 tablets artemether/lumefantrine (20/120mg) twice daily 3 days Alternative first line ARV plus AL 6
Control group AQ-AS 1 tablet artesunate/amodiaquine (100mg/270mg) once daily 3 days Artesunate/amodiaquine without any ARVs 6 Dose comparison
Experimental group 3TC -d4T-EFV plus DHA-PQ 3TC (150mg) d4T (30mg) twice daily plus Efavirenz (EFV 600mg) once daily plus 2 tablets dihydroartemisinin/piperaquine (40mg/320mg) once daily 3 days Alternative first line ARV plus DHA-PQ 6
Experimental group 3TC -d4T-NVP plus DHA-PQ 3TC (150mg)-d4T (30mg)-NVP (200mg) twice per day plus 2 tablets dihydroartemisinin/piperaquine (40mg/320mg) once daily 3 days First line ARVs plus DHA-PQ 6
Experimental group 3TC-AZT-TDF-LPV/r plus DHA-PQ 3TC (150mg)-AZT (300mg) twice daily plus-TDF (300mg) once daily-LPV/r(200/50mg) 2 tablets twice daily plus 2 tablets dihydroartemisinin/piperaquine (40mg/320mg) once daily 3 days Second line ARVs plus DHA-PQ 6
Control group DHA-PQ without any ARVs 2 tablets dihydroartemisinin/piperaquine (40mg/320mg) once daily 3 days dihydroartemisinin/piperaquine without any ARVs 6 Dose comparison
Experimental group 3TC-AZT-TDF-LPV/r plus AL 3TC (150mg) -AZT (300mg) twice daily plus Tenofovir (TDF; 300mg) once daily plus Lopinavir (200mg)/ritonavir (50mg) 2 tablets twice daily plus 2 tablets artemether/lumefantrine (20/120mg) 2X daily 3 days Second line ARVs plus AL 6
Experimental group 3TC -d4T-NVP plus AQ-AS 3TC (150mg) d4T (30mg) NVP (200mg) twice daily plus 1 tablet artesunate/amodiaquine (100mg/270mg) once daily 3 days First line ARVs plus AQ-AS 6
Experimental group 3TC-AZT-TDF-LPV/r plus AQ-AS 3TC (150mg) -AZT (300mg) twice daily plus Tenofovir (TDF; 300mg) once daily plus Lopinavir (200mg)/ritonavir (50mg) 2 tablets twice daily plus 1 tablet artesunate/amodiaquine (100mg/270mg) once daily 3 days Second line ARV plus AQ-AS 6

ELIGIBILITY CRITERIA
List inclusion criteria List exclusion criteria Min age Max age Gender
1. Blantyre City residents 2. Confirmed HIV positive clients a. Controls group (ART naïve): with CD4 Cell count more than 250 cells/mm3 b. Intervention group (ART-treated): with CD4 cell count more than 250 cells/mm3 and receiving first-line, alternative first line or second line ART, as described in the background section, for ¿6 months. 3. Age ¿18 years 4. Ability to read and write and provide informed consent 5. Body weight at least 40kgs (so that they are eligible to receive recommended adult doses of the antimalarial drug) 6. Stated willingness to be contacted by phone or at home. 7. Stated willingness to be admitted in the hospital for 3 days and to remain in Blantyre city for 2 months after enrolment. 1. Body Mass Index less than 18.5kg/m2 2. CD4 Cell count <250 cells/mm3 3. Hemoglobin <10 g/dL 4. Receiving other drugs which are known inhibitors or inducers of P450 enzymes of P-glycoprotein (except cotrimoxazole prophylaxis, which is the standard of care in HIV-infected people). 5. History of regular intake of alcohol (>twice/week), tobacco (>3 times/week) or any use of illicit drugs 6. History or evidence of pre-existing diseases of the liver and kidneys ie if the serum transaminases levels are >3 times the upper limit of normal or urea and creatinine levels >1.5 times the upper limit of normal. 7. History or evidence of heart disease, including conductive abnormalities on electrocardiographs (ECGs) ie QTc interval>450ms (men) and >470ms (females) 8. Clinical and/or laboratory evidence of other infections in addition to HIV, such as clinical malaria or microscopic asexual forms of Pf malaria, hepatitis B, pneumonia, tuberculosis, bacteremia etc. 9. Laboratory evidence of white blood cell disorders such as neutropenia, lymphopenia and thrombocytopenia. 10. Physically unfit with Karnofsky score of <80%. 11. Hypersensitivity to any of the ACTs. 12. Pregnancy ie confirmed by a Human Chorionic Gonadotrophin test. 13. Current participation in any other therapeutic or vaccine trial 18 Years 60 Years Both

ETHICS APPROVAL
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval
Name of the ethics committee
Yes 2009/08/04 Malawi College of Medicine Research and Ethics Committee
Ethics Committee Address
Street address City Postal code Country
Mahatma Gandhi Road, Mahatma Gandhi Campus Blantyre Bt3 Malawi
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval
Name of the ethics committee
Yes 2010/01/13 Liverpool School of Tropical Medicine (LSTM) Research Ethics Committee
Ethics Committee Address
Street address City Postal code Country
Pembroke Place Liverpool L3 5QA United Kingdom

OUTCOMES
Type of outcome Outcome Timepoint(s) at which outcome measured
Primary Outcome Area under the curve (AUC) for the ACT AUC computed from a concentration-time curve
Primary Outcome adverse events At anytime from administration of ACT to 28 days post dosing.

RECRUITMENT CENTRES
Name of recruitment centre Street address City Postal code Country
Queen Elizabeth Central Hospital Chipatala Avenue Blantyre Bt3 Malawi

FUNDING SOURCES
Name of source Street address City Postal code Country
EDCTP 334 Laan van Nieuw Oost Indie The Hague 2593 CE Netherlands
EDCTP 334 Laan van Nieuw Oost Indie The Hague 2593 CE Netherlands

SPONSORS
Sponsor level Name Street address City Postal code Country Nature of sponsor
Primary Sponsor Liverpool School of Tropical Medicine Pembroke Place Liverpool L3 5QA United Kingdom University
Primary Sponsor Liverpool School of Tropical Medicine Pembroke Place Liverpool L3 5QA United Kingdom University

COLLABORATORS
Name Street address City Postal code Country
Instituut voor Tropische Geneeskunde Nationalestraat 155 Antwerp B2000 Belgium
Vienna School of Clinical Research Kölblgasse 10 Vienna 1030 Austria
College of Medicine Research Support Center Mahatma Gandhi Road Blantyre Bt3 Malawi
Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW) Chipatala Avenue Blantyre Bt3 Malawi
Centro de Investigação em Saúde da Manhiça (CISM) None Manhiça None Mozambique
Tropical Diseases Research Centre Sixth Floor of Ndola Central Hospital Ndola 101010 Zambia
Fundació Privada Clínic per la Recerca Biomèdica c/Villaroel 170 Barcelona 08036 Spain
Liverpool School of Tropical Medicine Pembroke Place Liverpool L3 5QA United Kingdom
Instituut voor Tropische Geneeskunde Nationalestraat 155 Antwerp B2000 Belgium
Vienna School of Clinical Research Kölblgasse 10 Vienna 1030 Austria
College of Medicine Research Support Center Mahatma Gandhi Road Blantyre Bt3 Malawi
Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW) Chipatala Avenue Blantyre Bt3 Malawi
Centro de Investigação em Saúde da Manhiça (CISM) None Manhiça None Mozambique
Tropical Diseases Research Centre Sixth Floor of Ndola Central Hospital Ndola 101010 Zambia
Fundació Privada Clínic per la Recerca Biomèdica c/Villaroel 170 Barcelona 08036 Spain
Liverpool School of Tropical Medicine Pembroke Place Liverpool L3 5QA United Kingdom

CONTACT PEOPLE
Role Name Email Phone Fax
Principal Investigator Dr Victor Mwapasa vmwapasa@medcol.mw +265 1 876 444 +265 1 875 774
Street address City Postal code Country Position / Affiliation
Chipatala Avenue (P.O. Box 30096, Chichiri) Blantyre Bt3 Malawi Associate Professor/Malawi-Liverpool Wellcome Clinical Research Programme
Role Name Email Phone Fax
Public Enquiries Dr Dianne Terlouw d.j.terlouw@liv.ac.uk +44 151 7053354
Street address City Postal code Country Position / Affiliation
Pembroke Place Liverpool L3 5QA United Kingdom
Role Name Email Phone Fax
Scientific Enquiries Dr Victor Mwapasa vmwapasa@medcol.mw +265 1 876 444 +265 1 875 774
Street address City Postal code Country Position / Affiliation
Chipatala Avenue (P.O. Box 30096, Chichiri) Blantyre Bt3 Malawi Associate Professor/Malawi-Liverpool Wellcome Clinical Research Programme